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Abstract
Idiopathic portal hypertension belongs to the group of non-cirrhotic portal hypertension, its
etiology is still unknown but its prognosis is excellent. We report a case of 45 year old female with
inactive hepatitis B virus (HBV) carrier status and persistently elevated alpha-fetoprotein (AFP),
presented with features of portal hypertension and without evidence of cirrhosis or fibrosis on liver
biopsy.
Background
Inactive hepatitis B virus (HBV) carriers represent the larg-
est group in chronic HBV infected patients [1].
Non-cirrhotic portal hypertension represents a heteroge-
neous group of diseases in which liver cirrhosis is not
present and most often presented only with features of
portal hypertension and not of parenchyma dysfunction
[2]. Idiopathic portal hypertension (IPH) belongs to this
category and is still one of the most important misdiag-
noses of clinical practice. To inexperienced physicians pre-
senting esophageal varices and upper gastrointestinal
bleeding usually prompt an unfortunate diagnosis of cir-
rhosis. With the expectation of an excellent prognosis of
IPH, a practicing gastroenterologist should be aware that
"not all varices mean cirrhosis" [3]. In the present paper,
we report a case of non-cirrhotic portal hypertension in
patient with inactive HBV carrier status and persistently
increased levels of AFP. To the best of our knowledge,
there is no other such case reported in English literature.
Case presentation
We report a case of a 45 year old Greek female (168 cm
height, 62 kg weight), HBV inactive carrier, with thrombo-
cytopenia, diagnosed 26 years ago when she was investi-
gated due to bruises and petechchiae on both legs. She has
no previous medical or family history. She does not
smoke and reports neither drug nor alcohol abuse. She is
the mother of two daughters.
Laboratory tests revealed only low platelets (PLT: 98.000/
mm3). She was HbsAg, anti HBc and anti HBe positive,
with normal myelogramm, suggesting secondary hyper-
splenism.
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Repeating tests and close follow up over the years revealed
the same HBV status, normal liver function tests (LFTs)
and low levels of PCR HBV DNA with maximum level of
7.4 × 102 IU/ML and AFP 42–56 ng/ml persistently ele-
vated since April 2004.
Upper gastrointestinal endoscopy revealed gastric varices
type II without signs of bleeding and propranolol was pre-
scribed to her.
Repeating imaging tests such as CT, MRI scanning, Dop-
pler ultrasound and MR angiography confirmed the
absence of portal or splenic vein thrombosis.
Histological evaluation of liver biopsy concluded that the
overall histological findings were compatible with inac-
tive HBV carrier state without evidence of any excess
inflammation or features suggesting fibrosis or cirrhosis.
Immunohistochemistry confirmed HbsAg presence and
HbcAg absence. The reticulin stain was negative.
Further investigation did not prove any abnormality
regarding prothrombotic conditions, autoantibody
screening (including antiphosholipid), thyroid function.
Levels of a1- antitrypsin, ferritin, and ceruloplasmin were
normal. Serology excluded other viral coinfection with
HDV or HCV. Schistosomiasis was not found. Since diag-
nosis, patient's condition has been stable and her course,
so far, uneventful.
Discussion
Portal hypertension in chronic hepatitis is thought to
develop during progression of the chronic hepatitis to cir-
rhosis [4]. While the prognosis of the inactive HbsAg car-
rier state is usually benign [5].
Multiple episodes of reactivation or sustained reactivation
can cause progressive hepatic damage and even decom-
pensation [6].
Non-cirrhotic portal hypertension is the general term for
a heterogeneous group of diseases that are due to intrahe-
patic or extrahepatic etiologies [7].
Idiopathic portal hypertension belongs to this group and
is a most confusing and complex disorder [3]. It may be
diagnosed in a patient with symptoms of portal hyperten-
sion (varices), patent portal and splenic veins and in the
absence of signs of liver cirrhosis, or when no other reason
can be found for liver disease [8].
There are several theories regarding its pathogenesis,
unfortunately none have proved to be a single factor fully
explaining the pathogenesis. These theories include the
trace element-chemical theory, autoimmune theory,
infection thrombosis and genetic theory [3].
In our case, the patient belongs to this group and close
monitoring for the past 26 years has ruled out reactiva-
tion. She presented with thrombocytopenia and splenom-
egaly. Gastric varices and patent portal and splenic veins
detected but with no liver damage. However, it is ques-
tioned whether the fact that she is an inactive HBV carrier
could be ignored.
It is also hard to say whether her portal hypertension and
inactive HBV carrier status is a coincidence. On the other
hand, it is difficult to prove the case that an immunity
connection between the two conditions (with unknown
mechanism) could be the primary underlying disorder.
It is however widely accepted that autoimmune diseases
(especially connective tissue diseases) increase the preva-
lence of idiopathic portal hypertension in certain patient
groups [9].
In our patient neither an autoimmune condition nor
thrombophillic factors (protein c, s deficiency factor V
mutation) were found despite detailed investigation.
Drugs, alcohol, medication and toxins were excluded by
patient's history. Chronic exposure to arsenic or vinyl
chemicals even if suspected could not be proven.
One paper reports two cases of women with chronic hep-
atitis C who developed severe thrombocytopenia due to
portal hypertension without cirrhosis, indicating that por-
tal hypertension might precede the onset of cirrhosis in
type C hepatitis [4].
Moreover, it is worth mentioning that despite the elevated
serum AFP (i.e. ≥ 10 ng/L) our patient has not so far devel-
oped either hepatocellular (HCC) or any other extrahe-
patic cancer.
Elevated serum AFP has however been associated with var-
ious chronic liver diseases and hepatic regeneration, apart
from HCC [10]. The presence of HBsAg was related to ele-
vated AFP, in one old study, but no abnormal AFP was
found among inactive HBV carriers [11]. Mild elevation of
AFP has also been found to correlate with viral hepatitis
especially hepatitis C [12,13]. One case report described a
38 year old healthy man with persistence of AFP due to
autosomal dominant inheritance pattern [14]. We were
not able to confirm hereditary persistence of AFP in our
case because we could not analyze AFP levels in all mem-
bers in three generations of her family.
Our patient does not have chronic hepatitis and has not
developed cirrhosis after 26 years of diagnosis and closePublish with BioMed Central    and   every 
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follow up. To the best of our knowledge this is the first
case of inactive HBV carrier and persistently elevated AFP
presented with non cirrhotic portal hypertension in Eng-
lish literature. It would be useful for the physicians to be
aware of such a possibility in similar cases despite its
extremely rare incidence. Whether there is a causal rela-
tionship between the two conditions or non-cirrhotic por-
tal hypertension might precede the onset of serious liver
damage in type B hepatitis in our case remains to be seen.
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